Celularity signs exclusive peptide API manufacturing deal with Vesalius Longevity Labs
Celularity Inc. announced on October 29, 2026, an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to make U.S.-based peptide active pharmaceutical ingredients under Vesalius's Peptual brand at Celularity's New Jersey facility. The filing does not disclose any financial terms, revenue expectations or contract value, so its effect on Celularity's financial results cannot be assessed from the filing.
Key points
- Announced October 29, 2026; press release filed as Exhibit 99.1 to Form 8-K
- Celularity performs downstream purification, processing, analytical testing and manufacturing at its Florham Park, New Jersey facility
- Supply to U.S. compounding pharmacies is conditional on future FDA action following Pharmacy Compounding Advisory Committee recommendations
- The collaboration will not involve GLP-1 receptor agonists or other weight-loss peptides
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.